May 17, 2025 - 13:00

In a significant advancement for the agricultural sector, the FDA has approved a groundbreaking gene-editing technology aimed at breeding swine resistant to Porcine Reproductive and Respiratory Syndrome (PRRS). This disease has long posed a severe threat to pig populations, leading to substantial economic losses for farmers and the industry as a whole.
The newly approved technology utilizes precise gene-editing techniques to enhance the immune response of pigs, making them less susceptible to PRRS. This development is expected to revolutionize swine production, allowing farmers to raise healthier animals while reducing the reliance on antibiotics and other treatments traditionally used to combat disease.
Experts in the field are optimistic about the potential impact of this technology on food security and animal welfare. By fostering a more resilient swine population, the industry can improve productivity and sustainability. As the implementation of this gene-editing technology begins, it signals a new era in livestock management and disease prevention strategies.
October 28, 2026 - 23:36
CSX Works Through Tech Outage as Security Team Confirms No CyberattackCSX is working through a technology outage that began Tuesday, with the company`s security team confirming the disruption was not a cyberattack and that no data breach occurred, according to a...
October 28, 2026 - 06:35
The Human Side of Patient CRM Upgrades: Four Choices Tech Cannot SolveModernizing a patient relationship management system is often framed as a software problem, but the hardest parts are not technical. Jaymin Sutarwala of United Therapeutics argues that four key...
October 27, 2026 - 19:33
SPOOKY SPECTACULAR - GATEWAY HEADS-UP MAFIA 2026 GRAND FINALETwo days. More than 360 cars. Nearly $30,000 in payouts. One weekend that will not be forgotten anytime soon. Some races are good. Some are memorable. Then there are weekends that remind everyone...
October 27, 2026 - 00:50
Aptar Pharma Expands Pulmonary Delivery Capabilities with Pulmotree AcquisitionAptar Pharma, a division of AptarGroup Inc., has acquired Pulmotree, a life sciences company based in Munich, Germany. The move strengthens the company`s position in pulmonary drug delivery...